Updates in the Treatment of Secondary AML After the 2024 SOHO Annual Meeting - Episode 2

Defining Intensive Chemotherapy Fitness in AML

,

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.

EP. 1: The Diagnosis and Prevalence of Secondary AML
Now Viewing
EP. 2: Defining Intensive Chemotherapy Fitness in AML
EP. 3: Long-Term Data for CPX-351 in Secondary AML
EP. 4: Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML
EP. 5: Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML
EP. 6: Goals in the Treatment of Secondary AML
EP. 7: The Role of Genetic Profiling in Secondary AML

Related Content:

John Theurer Cancer Center, Hackensack University Medical CenterHematologic Oncology
An Era of Firsts in CML: Asciminib Challenges SOC TKIs
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation